vs
朗美通（LITE）与Medpace Holdings, Inc.（MEDP）财务数据对比。点击上方公司名可切换其他公司
Medpace Holdings, Inc.的季度营收约是朗美通的1.1倍（$708.5M vs $665.5M），Medpace Holdings, Inc.净利率更高（19.1% vs 11.8%，领先7.3%），朗美通同比增速更快（65.5% vs 32.0%），Medpace Holdings, Inc.自由现金流更多（$188.1M vs $43.1M），过去两年朗美通的营收复合增速更高（34.8% vs 17.7%）
朗美通控股（Lumentum Holdings Inc.）是全球知名光电产品供应商，前身为美国捷迪讯（JDSU）旗下光电器件及激光业务板块，2015年8月随捷迪讯分拆独立运营，总部位于美国加利福尼亚州米尔皮塔斯，主营光通信网络设备、激光器、定制光学解决方案等多元产品。
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
LITE vs MEDP — 直观对比
营收规模更大
MEDP
是对方的1.1倍
$665.5M
营收增速更快
LITE
高出33.4%
32.0%
净利率更高
MEDP
高出7.3%
11.8%
自由现金流更多
MEDP
多$145.0M
$43.1M
两年增速更快
LITE
近两年复合增速
17.7%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $665.5M | $708.5M |
| 净利润 | $78.2M | $135.1M |
| 毛利率 | 36.1% | — |
| 营业利润率 | 9.7% | 21.6% |
| 净利率 | 11.8% | 19.1% |
| 营收同比 | 65.5% | 32.0% |
| 净利润同比 | 228.4% | 15.5% |
| 每股收益（稀释后） | $0.89 | $4.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LITEMEDP
| Q4 25 | $665.5M | $708.5M | ||
| Q3 25 | $533.8M | $659.9M | ||
| Q2 25 | $480.7M | $603.3M | ||
| Q1 25 | $425.2M | $558.6M | ||
| Q4 24 | $402.2M | $536.6M | ||
| Q3 24 | $336.9M | $533.3M | ||
| Q2 24 | $308.3M | $528.1M | ||
| Q1 24 | $366.5M | $511.0M |
净利润LITEMEDP
| Q4 25 | $78.2M | $135.1M | ||
| Q3 25 | $4.2M | $111.1M | ||
| Q2 25 | $213.3M | $90.3M | ||
| Q1 25 | $-44.1M | $114.6M | ||
| Q4 24 | $-60.9M | $117.0M | ||
| Q3 24 | $-82.4M | $96.4M | ||
| Q2 24 | $-252.5M | $88.4M | ||
| Q1 24 | $-127.0M | $102.6M |
毛利率LITEMEDP
| Q4 25 | 36.1% | — | ||
| Q3 25 | 34.0% | — | ||
| Q2 25 | 33.3% | — | ||
| Q1 25 | 28.8% | — | ||
| Q4 24 | 24.8% | — | ||
| Q3 24 | 23.1% | — | ||
| Q2 24 | 16.6% | — | ||
| Q1 24 | 16.2% | — |
营业利润率LITEMEDP
| Q4 25 | 9.7% | 21.6% | ||
| Q3 25 | 1.3% | 21.5% | ||
| Q2 25 | -1.7% | 20.9% | ||
| Q1 25 | -8.9% | 20.3% | ||
| Q4 24 | -12.8% | 23.4% | ||
| Q3 24 | -24.5% | 21.1% | ||
| Q2 24 | -43.3% | 19.9% | ||
| Q1 24 | -31.3% | 20.4% |
净利率LITEMEDP
| Q4 25 | 11.8% | 19.1% | ||
| Q3 25 | 0.8% | 16.8% | ||
| Q2 25 | 44.4% | 15.0% | ||
| Q1 25 | -10.4% | 20.5% | ||
| Q4 24 | -15.1% | 21.8% | ||
| Q3 24 | -24.5% | 18.1% | ||
| Q2 24 | -81.9% | 16.7% | ||
| Q1 24 | -34.7% | 20.1% |
每股收益（稀释后）LITEMEDP
| Q4 25 | $0.89 | $4.65 | ||
| Q3 25 | $0.05 | $3.86 | ||
| Q2 25 | $3.10 | $3.10 | ||
| Q1 25 | $-0.64 | $3.67 | ||
| Q4 24 | $-0.88 | $3.67 | ||
| Q3 24 | $-1.21 | $3.01 | ||
| Q2 24 | $-3.75 | $2.75 | ||
| Q1 24 | $-1.88 | $3.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $497.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $846.6M | $459.1M |
| 总资产 | $4.8B | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LITEMEDP
| Q4 25 | $1.2B | $497.0M | ||
| Q3 25 | $1.1B | $285.4M | ||
| Q2 25 | $877.1M | $46.3M | ||
| Q1 25 | $866.7M | $441.4M | ||
| Q4 24 | $896.7M | $669.4M | ||
| Q3 24 | $916.1M | $656.9M | ||
| Q2 24 | $887.0M | $510.9M | ||
| Q1 24 | $870.9M | $407.0M |
股东权益LITEMEDP
| Q4 25 | $846.6M | $459.1M | ||
| Q3 25 | $780.8M | $293.6M | ||
| Q2 25 | $1.1B | $172.4M | ||
| Q1 25 | $879.5M | $593.6M | ||
| Q4 24 | $872.3M | $825.5M | ||
| Q3 24 | $895.9M | $881.4M | ||
| Q2 24 | $957.3M | $763.6M | ||
| Q1 24 | $1.2B | $671.5M |
总资产LITEMEDP
| Q4 25 | $4.8B | $2.0B | ||
| Q3 25 | $4.6B | $1.8B | ||
| Q2 25 | $4.2B | $1.6B | ||
| Q1 25 | $4.0B | $1.9B | ||
| Q4 24 | $4.0B | $2.1B | ||
| Q3 24 | $4.0B | $2.1B | ||
| Q2 24 | $3.9B | $1.9B | ||
| Q1 24 | $4.2B | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $126.7M | $192.7M |
| 自由现金流经营现金流 - 资本支出 | $43.1M | $188.1M |
| 自由现金流率自由现金流/营收 | 6.5% | 26.6% |
| 资本支出强度资本支出/营收 | 12.6% | 0.6% |
| 现金转化率经营现金流/净利润 | 1.62× | 1.43× |
| 过去12个月自由现金流最近4个季度 | $-29.5M | $681.9M |
8季度趋势，按日历期对齐
经营现金流LITEMEDP
| Q4 25 | $126.7M | $192.7M | ||
| Q3 25 | $57.9M | $246.2M | ||
| Q2 25 | $64.0M | $148.5M | ||
| Q1 25 | $-1.6M | $125.8M | ||
| Q4 24 | $24.3M | $190.7M | ||
| Q3 24 | $39.6M | $149.1M | ||
| Q2 24 | $35.5M | $116.4M | ||
| Q1 24 | $-7.0M | $152.7M |
自由现金流LITEMEDP
| Q4 25 | $43.1M | $188.1M | ||
| Q3 25 | $-18.3M | $235.5M | ||
| Q2 25 | $10.1M | $142.4M | ||
| Q1 25 | $-64.4M | $115.8M | ||
| Q4 24 | $-15.9M | $183.0M | ||
| Q3 24 | $-34.5M | $138.5M | ||
| Q2 24 | $10.9M | $103.5M | ||
| Q1 24 | $-26.6M | $147.2M |
自由现金流率LITEMEDP
| Q4 25 | 6.5% | 26.6% | ||
| Q3 25 | -3.4% | 35.7% | ||
| Q2 25 | 2.1% | 23.6% | ||
| Q1 25 | -15.1% | 20.7% | ||
| Q4 24 | -4.0% | 34.1% | ||
| Q3 24 | -10.2% | 26.0% | ||
| Q2 24 | 3.5% | 19.6% | ||
| Q1 24 | -7.3% | 28.8% |
资本支出强度LITEMEDP
| Q4 25 | 12.6% | 0.6% | ||
| Q3 25 | 14.3% | 1.6% | ||
| Q2 25 | 11.2% | 1.0% | ||
| Q1 25 | 14.8% | 1.8% | ||
| Q4 24 | 10.0% | 1.4% | ||
| Q3 24 | 22.0% | 2.0% | ||
| Q2 24 | 8.0% | 2.4% | ||
| Q1 24 | 5.3% | 1.1% |
现金转化率LITEMEDP
| Q4 25 | 1.62× | 1.43× | ||
| Q3 25 | 13.79× | 2.22× | ||
| Q2 25 | 0.30× | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LITE
| Components | $443.7M | 67% |
| Systems | $221.8M | 33% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
